Prostate cancer is the most common cause of cancer and second leading cause of cancer death for men in the United States. Localized disease is potentially curable with radiation or surgery;however, advanced disease remains incurable. Depletion of gonadal testosterone is the upfront standard therapy for advanced disease. Unfortunately, metastatic disease almost always recurs as castration-resistant prostate cancer (CRPC), which is generally the lethal form of this disease. Despite depletion of gonadal testosterone, CRPC remains driven by intratumoral synthesis of androgens. The survival benefit conferred by abiraterone acetate, which blocks CYP17A1, is the best evidence for the necessity of androgen synthesis in the progression of CRPC. Initial or acquired resistance to abiraterone acetate, which was approved by the United States Food and Drug Administration in April 2011 for the treatment of CRPC, has now become the next hurdle to overcome. Recent studies have shown that synthesis of dihydrotestosterone (DHT), the most potent androgen that drives CRPC progression, unexpectedly bypasses testosterone. This finding alters the landscape of potential drug targets and suggests that 3?-hydroxysteroid dehydrogenase/isomerase (3?HSD) is a potentially important and viable pharmacologic target. The overarching hypothesis of this proposal is that effective pharmacologic inhibition of 3?HSD will be an effective treatment for CRPC and tumors that are resistant to abiraterone acetate.
In Aim 1, the role and requirement of 3?HSD1 and 3?HSD2 expression for the development and progression of CRPC will be defined.
In Aim 2, the effect(s) of abiraterone acetate on the conversion from dehydroepiandrosterone to androstenedione by 3?HSD1 and 3?HSD2 will be characterized.
In Aim 3, a series of steroidal azoles will be synthesized and candidate inhibitors of recombinant 3?HSD1 and 3?HSD2 will be identified, which also inhibit CYP17A1. The ultimate anticipated benefit of this proposal is the development of new and improved approaches to the treatment of men with CRPC.

Public Health Relevance

Castration-resistant prostate cancer (CRPC), the lethal form of this disease, is the second leading cause of cancer death for men in the United States and is therefore a major public health problem. This proposal will identify the specific role of two isoenzymes required for CRPC progression, define their suitability as potential drug targets and identify candidate compounds that may serve as lead candidates for pharmacologic therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA168899-01A1
Application #
8442754
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Misra, Raj N
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
1
Fiscal Year
2013
Total Cost
$340,899
Indirect Cost
$96,603
Name
Cleveland Clinic Lerner
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Almassi, Nima; Reichard, Chad; Li, Jianbo et al. (2018) HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer. JAMA Oncol 4:554-557
Zhu, Ziqi; Chung, Yoon-Mi; Sergeeva, Olga et al. (2018) Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging. J Biol Chem 293:17829-17837
Ko, Hyun-Kyung; Berk, Michael; Chung, Yoon-Mi et al. (2018) Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer. Cell Rep 22:809-819
Alyamani, Mohammad; Emamekhoo, Hamid; Park, Sunho et al. (2018) HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. J Clin Invest 128:3333-3340
Hettel, Daniel; Zhang, Ao; Alyamani, Mohammad et al. (2018) AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation. Endocrinology 159:2884-2890
Gao, Xiaomei; Dai, Charles; Huang, Shengsong et al. (2018) Functional silencing of HSD17B2 in prostate cancer promotes disease progression. Clin Cancer Res :
Hearn, Jason W D; Xie, Wanling; Nakabayashi, Mari et al. (2018) Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer. JAMA Oncol 4:558-562
Alyamani, Mohammad; Li, Zhenfei; Upadhyay, Sunil K et al. (2017) Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column. J Steroid Biochem Mol Biol 172:231-239
Li, Jianneng; Alyamani, Mohammad; Zhang, Ao et al. (2017) Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. Elife 6:
Dai, Charles; Chung, Yoon-Mi; Kovac, Evan et al. (2017) Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues. Clin Cancer Res 23:6351-6362

Showing the most recent 10 out of 20 publications